Home › Funds › Commodore Capital LP › RLAY
Commodore Capital LP position in RLAY
RELAY THERAPEUTICS INC COM · Health Care
Commodore Capital LP reported holding 12,000,000 shares of RLAY (RELAY THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$224.5M, representing 13.37% of its reported portfolio and ranking #1 among its reported holdings. Commodore Capital LP has disclosed RLAY holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Commodore Capital LP's RLAY position evolved
Commodore Capital LP first disclosed a stake in RLAY in Q2 2025 at 13,350,000 shares (US$46.2M). The position peaked in Q2 2026 at 12,000,000 shares, worth US$224.5M. Across 5 filings, Commodore Capital LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 12,000,000 shares valued at US$224.5M — a reduction of -5,000,000 shares quarter over quarter.. Notable position changes include a 27% increase in Q3 2025 (shares rose 62% over the following quarter), a 29% trim in Q2 2026 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 13.35M | $46.19M | New |
| Q3 2025 | 17.00M | $88.74M | Add |
| Q4 2025 | 17.00M | $143.82M | Hold |
| Q1 2026 | 17.00M | $169.15M | Hold |
| Q2 2026 | 12.00M | $224.52M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLAY and 13F data
RLAY (RELAY THERAPEUTICS INC COM) is a Health Care company. 64 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLAY
- SB INVESTMENT ADVISERS (UK) LTD 27.90M sh · $522.10M · Q2 2026
- Casdin Capital 16.04M sh · $300.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 14.11M sh · $263.93M · Q2 2026
- Nextech Invest Ltd. 6.78M sh · $126.79M · Q2 2026
- Bellevue Group AG 6.19M sh · $115.74M · Q2 2026
- TCG Crossover Management, LLC 4.27M sh · $79.95M · Q2 2026
- Siren, L.L.C. 3.65M sh · $68.29M · Q2 2026
- Kynam Capital Management, LP 3.30M sh · $61.74M · Q2 2026
- Spruce Street Capital LP 2.98M sh · $55.83M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $52.89M · Q2 2026
- MPM BioImpact LLC 2.42M sh · $45.20M · Q2 2026
- Elmind Capital, LP 1.47M sh · $27.42M · Q2 2026
More on Commodore Capital LP
FAQ
How long has Commodore Capital LP held RLAY?
Commodore Capital LP has disclosed RLAY holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Commodore Capital LP's current position in RLAY?
As of Q2 2026, Commodore Capital LP holds 12.00M shares of RLAY (RELAY THERAPEUTICS INC COM), valued at $224.52M, representing 13.37% of its reported portfolio and ranking #1.
Has Commodore Capital LP been buying or selling RLAY?
In the latest 13F filing (Q2 2026), Commodore Capital LP reduced its position in RLAY. The position peaked in Q2 2026 at 12.00M shares.
Which other funds hold RLAY?
Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.